PRKCB and neoplasm: To date, 12 isoforms of PKC have been described that differ in primary structure, tissue distribution, subcellular localization and substrate specificity.[7] The PKC-β isoform is a key component in the VEGF/VEGFR signaling cascade, and inhibiting PKC-β results in reduced tumor vascularization that ultimately leads to tumor regression.